Engineering the regulatory pathways of a replicating oncolytic adenovirus enhances selective destruction of tumor cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ramachandra, M. et al. Nat. Biotechnol. 19, 1035–1041 (2001).
Bischoff, J. et al. Science 274, 373–376 (1996).
Khuri, F.R. et al. Nat. Med. 6, 879–885 (2000).
Rothmann, T., Hengstermann, A., Whitaker, N.J., Scheffner, M. & zur Hausen, H. J. Virol. 72, 9470–9478 (1998).
Kirn, D., Martuza, R.L. & Zwiebel, J. Nat. Med. 7, 781–787 (2001).
Alemany, R., Balague, C. & Curiel, D.T. Nat. Biotechnol. 18, 723–727 (2000).
Logg, C.R., Tai, C.K., Logg, A., Anderson, W.F. & Kasahara, N. Hum. Gene Ther. 12, 921–932 (2001).
Grote, D. et al. Blood 97, 3746–3754 (2001).
Peng, K-W. et al. Blood 98, 2002–2007 (2001).
Vile, R.G., Russell, S.J. & Lemoine, N.R. Gene Ther. 7, 2–8 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vile, R. Vironcology—not yet, but soon?. Nat Biotechnol 19, 1020–1022 (2001). https://doi.org/10.1038/nbt1101-1020
Issue Date:
DOI: https://doi.org/10.1038/nbt1101-1020